Cedar Mountain Advisors
RPRX icon

Cedar Mountain Advisors’s Royalty Pharma RPRX Stock Holding History

Cedar Mountain Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.4K Hold
178
– – ﹤0.01% 450
2026
Q2 		$10K Hold
178
– – ﹤0.01% 498
2026
Q1 		$8.54K Buy
+178
New +$7.8K ﹤0.01% 506

Other funds holding RPRX

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Kepler Cheuvreux
Kepler Cheuvreux Nyon $1.65B AUM 36.86% 1-Year Est. Return
Kirr Marbach & Co
Kirr Marbach & Co Columbus, Indiana $530M AUM 14.37% 1-Year Est. Return
Triasima Portfolio Management
Triasima Portfolio Management Montreal, Quebec, Canada $758M AUM 48.16% 1-Year Est. Return
Sumitomo Mitsui DS Asset Management
Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.8B AUM 30.39% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Cedar Mountain Advisors's RPRX Position: Q3 2026 in Review

Cedar Mountain Advisors held its Royalty Pharma (RPRX) position steady in Q3 2026 at 178 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #450.

Cedar Mountain Advisors first reported a position in RPRX in Q1 2026 and has held it in 3 quarters since. 89 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Cedar Mountain Advisors held 178 shares of Royalty Pharma worth $10.4K as of Q3 2026.
  • Cedar Mountain Advisors left its Royalty Pharma share count unchanged in Q3 2026.
  • Royalty Pharma made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q3 2026, its #450 holding.
  • Cedar Mountain Advisors first reported a position in Royalty Pharma in Q1 2026 and has held it in 3 quarters since.
  • 89 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Cedar Mountain Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.